BERKELEY, CA (UroToday.com) - The most common (non-skin) cancer in men in the USA and Europe is prostate cancer.(1,2)
Additionally, mortality associated with this disease is the second and third highest of all cancers in these two populations, respectively.(1-3) Within the larger group of men with prostate cancer, there exists a subset of individuals who will require androgen-deprivation therapy (ADT). Although ADT is effective in lowering PSA in most men, the therapeutic response will eventually wane and the disease will progress at some point. For many years, development of new therapies and new treatment strategies were slow to emerge for prostate cancer in general and for castration-resistant prostate cancer (CRPC) in particular. However, that has changed in recent years with the emergence of various new agents accessing several different mechanistic disease pathways. Together with these expanded options for treatment has arisen a commensurate need to redefine both therapeutic strategies and the roles of practitioners from different specialties as well...View or save the full text Mini Review as a .pdf file
What’s known on the subject? and What does the study add? The interplay between urologists and oncologists in the treatment of prostate cancer has been long standing. Recent paradigm shifts in treatment are reviewed with an emphasis on how these treatments may eventually alter the dynamic equilibrium between urology and oncology specialists. |
A. Oliver Sartor and John M. Fitzpatrick*
Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA, USA and *Department of Surgery, Mater Misericordiae Hospital, University College, Dublin, Ireland
More BJUI Mini Reviews and Archives